Higher dose of Arena Pharma's bowel disease drug meets study goal
March 19, 2018 at 16:03 PM EDT
March 19 (Reuters) - Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study.